Randomized Trialhigh evidence
Efficacy and safety of the TRPV1 agonist RTX-GRT7039 in patients with pain associated with knee osteoarthritis: results from a phase 3, randomised, placebo-controlled trial.
Osteoarthritis and cartilage·October 22, 2026·PMID 42913877
Why it mattersKnee osteoarthritis pain remains challenging to manage, and novel intra-articular therapies are needed. This trial provides high-level evidence that TRPV1 agonism via RTX-GRT7039 does not offer meaningful analgesic benefit over placebo, informing treatment decisions and guiding future research away from this mechanism.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled